BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chatterjee S, Biondi-Zoccai G, Abbate A, D’Ascenzo F, Castagno D, Van Tassell B, Mukherjee D, Lichstein E. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346:f55. [PMID: 23325883 DOI: 10.1136/bmj.f55] [Cited by in Crossref: 165] [Cited by in F6Publishing: 144] [Article Influence: 20.6] [Reference Citation Analysis]
Number Citing Articles
1 Sarría-Santamera A, Prado-Galbarro FJ, Martín-Martínez MA, Carmona R, Gamiño Arroyo AE, Sánchez-Piedra C, Garrido Elustondo S, del Cura González I. [Survival of patients with heart failure in primary care]. Aten Primaria 2015;47:438-45. [PMID: 25487462 DOI: 10.1016/j.aprim.2014.03.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Paul TK, Mukherjee D. Silent myocardial infarction and risk of heart failure. Ann Transl Med 2018;6:S35. [PMID: 30613610 DOI: 10.21037/atm.2018.09.45] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Whang W, Holmes DR, Miller MA, Langan MN, Choudry S, Sofi A, Koruth JS, Dukkipati SR, Reddy VY. Does Left Atrial Appendage Closure Reduce Mortality? A Vital Status Analysis of the Randomized PROTECT AF and PREVAIL Clinical Trials. J Atr Fibrillation 2018;11:2119. [PMID: 31139291 DOI: 10.4022/jafib.2119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Moore XL, Su Y, Fan Y, Zhang YY, Woodcock EA, Dart AM, Du XJ. Diverse regulation of cardiac expression of relaxin receptor by α1- and β1-adrenoceptors. Cardiovasc Drugs Ther 2014;28:221-8. [PMID: 24852484 DOI: 10.1007/s10557-014-6525-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
5 Giannetta E, Feola T, Gianfrilli D, Pofi R, Dall'Armi V, Badagliacca R, Barbagallo F, Lenzi A, Isidori AM. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med 2014;12:185. [PMID: 25330139 DOI: 10.1186/s12916-014-0185-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
6 Puljević M, Velagić V, Puljević D, Miličić D. Propranolol efficiency in prevention of sustained ventricular tachycardia in patients with implanted cardioverter-defibrillator: a case series. Croat Med J 2014;55:75-6. [PMID: 24577831 DOI: 10.3325/cmj.2014.55.75] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Chin J, Fulcher J, Jenkins A, Keech A. Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. Heart, Lung and Circulation 2015;24:480-7. [DOI: 10.1016/j.hlc.2014.11.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Chourdakis E, Koniari I, Velissaris D, Tsigkas G, G Kounis N, Osman N. Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives. J Geriatr Cardiol 2021;18:362-75. [PMID: 34149825 DOI: 10.11909/j.issn.1671-5411.2021.05.008] [Reference Citation Analysis]
9 Loudon BL, Noordali H, Gollop ND, Frenneaux MP, Madhani M. Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm. Br J Pharmacol 2016;173:1911-24. [PMID: 26993743 DOI: 10.1111/bph.13480] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
10 Mohamed RMSM, Elshazly SM, Nafea OE, Abd El Motteleb DM. Comparative cardioprotective effects of carvedilol versus atenolol in a rat model of cardiorenal syndrome type 4. Naunyn Schmiedebergs Arch Pharmacol 2021. [PMID: 34398250 DOI: 10.1007/s00210-021-02130-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH. β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart 2015;2:e000230. [PMID: 25821584 DOI: 10.1136/openhrt-2014-000230] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
12 Hasan W. Autonomic cardiac innervation: development and adult plasticity. Organogenesis. 2013;9:176-193. [PMID: 23872607 DOI: 10.4161/org.24892] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
13 Takaoka R, Soejima Y, Guro S, Yoshioka H, Sato H, Suzuki H, Hisaka A. Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure. CPT Pharmacometrics Syst Pharmacol 2021. [PMID: 34218511 DOI: 10.1002/psp4.12676] [Reference Citation Analysis]
14 Cannillo M, D'Ascenzo F, Grosso Marra W, Cerrato E, Calcagno A, Omedè P, Bonora S, Mancone M, Vizza D, DiNicolantonio JJ, Pianelli M, Barbero U, Gili S, Annone U, Raviola A, Salera D, Mistretta E, Vilardi I, Colaci C, Abbate A, Zoccai GB, Moretti C, Gaita F. Heart failure in patients with human immunodeficiency virus: a review of the literature. J Cardiovasc Med (Hagerstown) 2015;16:383-9. [PMID: 25058690 DOI: 10.2459/JCM.0000000000000168] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
15 Yoo SM, Choi SH, Jung MDY, Lim SC, Baek SH. Short-term use of telmisartan attenuates oxidation and improves Prdx2 expression more than antioxidant β-blockers in the cardiovascular systems of spontaneously hypertensive rats. Hypertens Res 2015;38:106-15. [DOI: 10.1038/hr.2014.151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
16 El Moheb M, Nicolas J, Khamis AM, Iskandarani G, Akl EA, Refaat M. Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy. Cochrane Database Syst Rev 2018;12:CD012738. [PMID: 30537022 DOI: 10.1002/14651858.CD012738.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ruiz M, Labarthe F, Fortier A, Bouchard B, Thompson Legault J, Bolduc V, Rigal O, Chen J, Ducharme A, Crawford PA, Tardif JC, Des Rosiers C. Circulating acylcarnitine profile in human heart failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond. Am J Physiol Heart Circ Physiol 2017;313:H768-81. [PMID: 28710072 DOI: 10.1152/ajpheart.00820.2016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 10.0] [Reference Citation Analysis]
18 Shu Q, Wu L, Zhang R, Zhang Q, Huang J, Meng Y. Age-dependent changes in cardiac performance, motor function, QoL, and mental status in metoprolol-treated chronic heart failure patients. Sci Rep 2019;9:453. [PMID: 30679746 DOI: 10.1038/s41598-018-37520-8] [Reference Citation Analysis]
19 Qintar M, Hirai T, Arnold SV, Sheehy J, Sapontis J, Jones P, Tang Y, Lombardi W, Karmpaliotis D, Moses J, Patterson C, Nicholson WJ, Cohen DJ, Spertus JA, Grantham JA, Salisbury AC. De-escalation of antianginal medications after successful chronic total occlusion percutaneous coronary intervention: Frequency and relationship with health status. Am Heart J 2019;214:1-8. [PMID: 31152872 DOI: 10.1016/j.ahj.2019.04.013] [Reference Citation Analysis]
20 Joseph P, Swedberg K, Leong DP, Yusuf S. The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5). Journal of the American College of Cardiology 2019;74:672-82. [DOI: 10.1016/j.jacc.2019.04.067] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
21 Hong J, Barry AR. Long-Term Beta-Blocker Therapy after Myocardial Infarction in the Reperfusion Era: A Systematic Review. Pharmacotherapy 2018;38:546-54. [DOI: 10.1002/phar.2110] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
22 Chimenti I, Pagano F, Cavarretta E, Angelini F, Peruzzi M, Barretta A, Greco E, De Falco E, Marullo AG, Sciarretta S, Biondi-Zoccai G, Frati G. Β-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells. Sci Rep 2016;6:36774. [PMID: 27841293 DOI: 10.1038/srep36774] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
23 Shirazi-Tehrani E, Firouzabadi N, Tamaddon G, Bahramali E, Vafadar A. Carvedilol Alters Circulating MiR-1 and MiR-214 in Heart Failure. Pharmgenomics Pers Med 2020;13:375-83. [PMID: 32943906 DOI: 10.2147/PGPM.S263740] [Reference Citation Analysis]
24 Biondi-Zoccai G, Anderson LA. What is the purpose of launching World Journal of Meta-AnalysisWorld J Meta-Anal 2013; 1(1): 1-4 [DOI: 10.13105/wjma.v1.i1.1] [Reference Citation Analysis]
25 Shukkoor AA, George NE, Radhakrishnan S, Velusamy S, Kaliappan T, Gopalan R, Anandan P, Palanimuthu R, Balasubramanian VR. Impact of Clinical Audit on Adherence to the Guidelines Directed Medical Therapy in Patients Admitted with Heart Failure. Curr Drug Saf 2020;15:117-23. [PMID: 32156240 DOI: 10.2174/1574886315666200310114528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Fröhlich H, Zhao J, Täger T, Cebola R, Schellberg D, Katus HA, Grundtvig M, Hole T, Atar D, Agewall S, Frankenstein L. Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study. Circ Heart Fail 2015;8:887-96. [PMID: 26175538 DOI: 10.1161/CIRCHEARTFAILURE.114.001701] [Cited by in Crossref: 17] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
27 Castaldo C, Chimenti I. Cardiac Progenitor Cells: The Matrix Has You. Stem Cells Transl Med 2018;7:506-10. [PMID: 29688622 DOI: 10.1002/sctm.18-0023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
28 Mora MT, Gong JQX, Sobie EA, Trenor B. The role of β-adrenergic system remodeling in human heart failure: A mechanistic investigation. J Mol Cell Cardiol 2021;153:14-25. [PMID: 33326834 DOI: 10.1016/j.yjmcc.2020.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Kim MN, Park SM. Heart failure with preserved ejection fraction: insights from recent clinical researches. Korean J Intern Med 2020;35:514-34. [PMID: 32392659 DOI: 10.3904/kjim.2020.104] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
30 Al-Gobari M, Al-Aqeel S, Gueyffier F, Burnand B. Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews. BMJ Open 2018;8:e021108. [PMID: 30056380 DOI: 10.1136/bmjopen-2017-021108] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
31 Kaldara E, Sanoudou D, Adamopoulos S, Nanas JN. Outpatient management of chronic heart failure. Expert Opin Pharmacother 2015;16:17-41. [PMID: 25480690 DOI: 10.1517/14656566.2015.978286] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Xie W, Zheng F, Evangelou E, Liu O, Yang Z, Chan Q, Elliott P, Wu Y. Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis. Journal of Hypertension 2018;36:1256-65. [DOI: 10.1097/hjh.0000000000001720] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.7] [Reference Citation Analysis]
33 Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2013;13:52. [PMID: 23848972 DOI: 10.1186/1471-2261-13-52] [Cited by in Crossref: 65] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
34 Pathak A, Mrabeti S. β-Blockade for Patients with Hypertension, Ischemic Heart Disease or Heart Failure: Where are We Now? Vasc Health Risk Manag 2021;17:337-48. [PMID: 34135591 DOI: 10.2147/VHRM.S285907] [Reference Citation Analysis]
35 O’Neal WT, Efird JT, Landrine H, Anderson CA, Davies SW, O’Neal JB, Ferguson TB, Chitwood WR, Kypson AP. The effect of preoperative β-blocker use and race on long-term survival after coronary artery bypass grafting. J Cardiothorac Vasc Anesth. 2014;28:595-600. [PMID: 24139457 DOI: 10.1053/j.jvca.2013.06.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
36 Bølling R, Scheller NM, Køber L, Poulsen HE, Gislason GH, Torp-pedersen C. Comparison of the clinical outcome of different beta-blockers in heart failure patients: a retrospective nationwide cohort study: Clinical outcomes of different beta-blockers in HF patients. Eur J Heart Fail 2014;16:678-84. [DOI: 10.1002/ejhf.81] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
37 Sin DD. Should COPD stand for “comorbidity-related obstructive pulmonary disease”? Eur Respir J 2015;46:901-2. [DOI: 10.1183/13993003.01112-2015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Reed BN, Sueta CA. A practical guide for the treatment of symptomatic heart failure with reduced ejection fraction (HFrEF). Curr Cardiol Rev 2015;11:23-32. [PMID: 24251455 DOI: 10.2174/1574884708666131117125508] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
39 Martínez-Milla J, Raposeiras-Roubín S, Pascual-Figal DA, Ibáñez B. Role of Beta-blockers in Cardiovascular Disease in 2019. Rev Esp Cardiol (Engl Ed) 2019;72:844-52. [PMID: 31402328 DOI: 10.1016/j.rec.2019.04.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
40 Katsi V, Georgiopoulos G, Laina A, Koutli E, Parissis J, Tsioufis C, Nihoyannopoulos P, Tousoulis D. Left ventricular ejection fraction as therapeutic target: is it the ideal marker? Heart Fail Rev 2017;22:641-55. [PMID: 28601914 DOI: 10.1007/s10741-017-9624-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
41 Sato K, Kumar A, Jones BM, Mick SL, Krishnaswamy A, Grimm RA, Desai MY, Griffin BP, Rodriguez LL, Kapadia SR, Obuchowski NA, Popović ZB. Reversibility of Cardiac Function Predicts Outcome After Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis. J Am Heart Assoc 2017;6:e005798. [PMID: 28698259 DOI: 10.1161/JAHA.117.005798] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 7.8] [Reference Citation Analysis]
42 Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013;347:f5577. [PMID: 24473061 DOI: 10.1136/bmj.f5577] [Cited by in Crossref: 322] [Cited by in F6Publishing: 258] [Article Influence: 40.3] [Reference Citation Analysis]
43 Ozaydin M, Yucel H, Kocyigit S, Adali MK, Aksoy F, Kahraman F, Uysal BA, Erdogan D, Varol E, Dogan A. Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction. Med Princ Pract 2016;25:316-22. [PMID: 27164841 DOI: 10.1159/000446184] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
44 Sinagra G, Corrà U, Contini M, Magrì D, Paolillo S, Perrone Filardi P, Sciomer S, Badagliacca R, Agostoni P. Choosing among β-blockers in heart failure patients according to β-receptors' location and functions in the cardiopulmonary system. Pharmacol Res 2020;156:104785. [PMID: 32224252 DOI: 10.1016/j.phrs.2020.104785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
45 AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease. Cardiovasc Drugs Ther 2021. [PMID: 34106365 DOI: 10.1007/s10557-021-07205-y] [Reference Citation Analysis]
46 Sorigue M, Kuittinen O. Robustness and pragmatism of the evidence supporting the European Society for Medical Oncology guidelines for the diagnosis, treatment, and follow-up of follicular lymphoma. Expert Rev Hematol 2021;14:655-68. [PMID: 34128764 DOI: 10.1080/17474086.2021.1943351] [Reference Citation Analysis]
47 Prins KW, Thenappan T, Weir EK, Kalra R, Pritzker M, Archer SL. Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. J Am Heart Assoc 2019;8:e011343. [PMID: 30590974 DOI: 10.1161/JAHA.118.011343] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 21.0] [Reference Citation Analysis]
48 Sokos GG, Raina A. Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan. Vasc Health Risk Manag. 2020;16:41-51. [PMID: 32021227 DOI: 10.2147/vhrm.s197291] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
49 AlHabeeb W, Al-Ayoubi F, AlGhalayini K, Al Ghofaili F, Al Hebaishi Y, Al-Jazairi A, Al-Mallah MH, AlMasood A, Al Qaseer M, Al-Saif S, Chaudhary A, Elasfar A, Tash A, Arafa M, Hassan W. Saudi Heart Association (SHA) guidelines for the management of heart failure. J Saudi Heart Assoc 2019;31:204-53. [PMID: 31371908 DOI: 10.1016/j.jsha.2019.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
50 Lin L, Chu H, Hodges JS. On evidence cycles in network meta-analysis. Stat Interface 2020;13:425-36. [PMID: 32742550 DOI: 10.4310/sii.2020.v13.n4.a1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Bieber M, Werner RA, Tanai E, Hofmann U, Higuchi T, Schuh K, Heuschmann PU, Frantz S, Ritter O, Kraft P, Kleinschnitz C. Stroke-induced chronic systolic dysfunction driven by sympathetic overactivity. Ann Neurol 2017;82:729-43. [PMID: 29023958 DOI: 10.1002/ana.25073] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
52 Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. Eur Respir J 2016;48:880-8. [PMID: 27390282 DOI: 10.1183/13993003.01847-2015] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
53 Fongemie J, Felix-Getzik E. A Review of Nebivolol Pharmacology and Clinical Evidence. Drugs 2015;75:1349-71. [PMID: 26177892 DOI: 10.1007/s40265-015-0435-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
54 Taneva B, Caparoska D. The Impact of Treatment with Beta-Blockers upon Mortality in Chronic Heart Failure Patients. Open Access Maced J Med Sci 2016;4:94-7. [PMID: 27275338 DOI: 10.3889/oamjms.2016.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
55 Mittal R, Jhaveri VM, Kay SS, Greer A, Sutherland KJ, Mcmurry HS, Lin N, Mittal J, Malhotra AK, Patel AP. Recent Advances in Understanding the Pathogenesis of Cardiovascular Diseases and Development of Treatment Modalities. CHDDT 2019;19:19-32. [DOI: 10.2174/1871529x18666180508111353] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
56 Loiacono F, Fragasso G, Calori G, Alberti L, Marinosci G, Salerno A, Margonato A. Validation of a new score for outcome prediction in patients with heart failure with reduced ejection fraction. Minerva Cardioangiol 2019;67. [DOI: 10.23736/s0026-4725.19.04823-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Roever L, Biondi-Zoccai G. Network Meta-analysis to Synthesize Evidence for Decision Making in Cardiovascular Research. Arq Bras Cardiol 2016;106:333-7. [PMID: 27142793 DOI: 10.5935/abc.20160052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
58 Pereira-Barretto AC. Addressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of Ivabradine. Am J Cardiovasc Drugs 2016;16:93-101. [PMID: 26817946 DOI: 10.1007/s40256-016-0159-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Sant'Anna RT, Eibel B, Markoski MM, Rodrigues CG, de Salles FB, Giusti II, Nesralla IA, Nardi NB, Kalil RAK. Gene therapy for refractory angina and cell therapy for heart failure: experience of a Brazilian research group. Gene Ther 2020;27:40-50. [PMID: 31278371 DOI: 10.1038/s41434-019-0087-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Reed BN, Street SE, Jensen BC. Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure. Heart Fail Clin 2014;10:543-57. [PMID: 25217430 DOI: 10.1016/j.hfc.2014.07.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
61 Bajaj NS, Gupta K, Gharpure N, Pate M, Chopra L, Kalra R, Prabhu SD. Effect of immunomodulation on cardiac remodelling and outcomes in heart failure: a quantitative synthesis of the literature. ESC Heart Fail 2020;7:1319-30. [PMID: 32198851 DOI: 10.1002/ehf2.12681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Leong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm JD, Yusuf S. Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. Circ Res 2017;121:695-710. [PMID: 28860319 DOI: 10.1161/CIRCRESAHA.117.311849] [Cited by in Crossref: 90] [Cited by in F6Publishing: 40] [Article Influence: 22.5] [Reference Citation Analysis]
63 Patil SP, Ayappa IA, Caples SM, Kimoff RJ, Patel SR, Harrod CG. Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. J Clin Sleep Med 2019;15:301-34. [PMID: 30736888 DOI: 10.5664/jcsm.7638] [Cited by in Crossref: 120] [Cited by in F6Publishing: 85] [Article Influence: 60.0] [Reference Citation Analysis]
64 You SC, An MH, Yoon D, Ban GY, Yang PS, Yu HT, Park RW, Joung B. Rate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease. Heart Rhythm 2018;15:1825-32. [PMID: 30509364 DOI: 10.1016/j.hrthm.2018.06.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
65 Zaman S, Zaman SS, Scholtes T, Shun-Shin MJ, Plymen CM, Francis DP, Cole GD. The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets. Eur J Heart Fail 2017;19:1401-9. [PMID: 28597606 DOI: 10.1002/ejhf.838] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
66 Dézsi CA, Szentes V. The Real Role of β-Blockers in Daily Cardiovascular Therapy. Am J Cardiovasc Drugs 2017;17:361-73. [PMID: 28357786 DOI: 10.1007/s40256-017-0221-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]
67 Proietti R, Russo V, AlTurki A. Anti-arrhythmic therapy in patients with non-ischemic cardiomyopathy. Pharmacol Res 2019;143:27-32. [PMID: 30844534 DOI: 10.1016/j.phrs.2019.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Perreault S, de Denus S, White M, White-Guay B, Bouvier M, Dorais M, Dubé MP, Rouleau JL, Tardif JC, Jenna S, Haibe-Kains B, Leduc R, Deblois D. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality. Pharmacoepidemiol Drug Saf 2017;26:81-90. [PMID: 27859924 DOI: 10.1002/pds.4132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
69 Abi Khalil C, Sulaiman K, Asaad N, AlHabib KF, Alsheikh-Ali A, Jameesh M, Al-Jarallah M, Bulbanat B, AlMahmeed W, Ridha M, Bazargani N, Amin H, Al-Motarreb A, AlFaleh H, Panduranga P, Mahfoud Z, Al Suwaidi J. Beta-Blockers and Cardiovascular Outcomes in Acute Heart Failure with a History of Coronary Artery Disease and an Ejection Fraction ≥ 40. Curr Vasc Pharmacol 2020;18:644-51. [PMID: 31889498 DOI: 10.2174/1570161118666191231114203] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Niriayo YL, Asgedom SW, Demoz GT, Gidey K. Treatment optimization of beta-blockers in chronic heart failure therapy. Sci Rep 2020;10:15903. [PMID: 32981932 DOI: 10.1038/s41598-020-72836-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Alabed S, Sabouni A, Al Dakhoul S, Bdaiwi Y. Beta-blockers for congestive heart failure in children. Cochrane Database Syst Rev 2020;7:CD007037. [PMID: 32700759 DOI: 10.1002/14651858.CD007037.pub4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
72 O'Connell TD, Jensen BC, Baker AJ, Simpson PC. Cardiac alpha1-adrenergic receptors: novel aspects of expression, signaling mechanisms, physiologic function, and clinical importance. Pharmacol Rev 2014;66:308-33. [PMID: 24368739 DOI: 10.1124/pr.112.007203] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 13.1] [Reference Citation Analysis]
73 Adlan AM. Inflammation and Heart Rate–corrected QT Interval: Evidence for a Potentially Reversible Cause of Sudden Death in Patients with Rheumatoid Arthritis? J Rheumatol 2018;45:1609-10. [DOI: 10.3899/jrheum.180921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
74 Al-ghamdi BS, Rohra DK, Abuharb GAI, Alkofide HA, Alruwaili NS, Shoukri MM, Cahusac PMB. Use of beta blockers is associated with hearing loss. International Journal of Audiology 2018;57:213-20. [DOI: 10.1080/14992027.2017.1405162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Andersson C, Hansen PW, Steffensen IE, Andreasen C, Weeke PE, Køber L, Gislason GH, Torp-pedersen C. Mortality associated with cardiovascular drugs in patients with chronic obstructive pulmonary disease and right-sided heart failure – A danish nationwide registry-based study. European Journal of Internal Medicine 2019;63:56-61. [DOI: 10.1016/j.ejim.2019.02.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
76 Machuki JO, Zhang HY, Harding SE, Sun H. Molecular pathways of oestrogen receptors and β-adrenergic receptors in cardiac cells: Recognition of their similarities, interactions and therapeutic value. Acta Physiol (Oxf) 2018;222. [PMID: 28994249 DOI: 10.1111/apha.12978] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
77 Barrese V, Taglialatela M. New advances in beta-blocker therapy in heart failure. Front Physiol 2013;4:323. [PMID: 24294204 DOI: 10.3389/fphys.2013.00323] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
78 Chua CC, Hutchinson A, Tacey M, Parikh S, Lim WK, Aboltins C. A physician targeted intervention improves prescribing in chronic heart failure in general medical units. BMC Health Serv Res 2018;18:206. [PMID: 29566753 DOI: 10.1186/s12913-018-3009-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
79 Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, Cope S. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. Circ Heart Fail 2017;10:e003529. [PMID: 28087688 DOI: 10.1161/CIRCHEARTFAILURE.116.003529] [Cited by in Crossref: 93] [Cited by in F6Publishing: 38] [Article Influence: 23.3] [Reference Citation Analysis]
80 Briasoulis A, Palla M, Afonso L. Meta-Analysis of the Effects of Carvedilol Versus Metoprolol on All-Cause Mortality and Hospitalizations in Patients With Heart Failure. The American Journal of Cardiology 2015;115:1111-5. [DOI: 10.1016/j.amjcard.2015.01.545] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
81 Cai Y, Lu X, Cheng X, Lv Q, Xu G, Liu X. Increased Renal Dysfunction, Apoptosis, and Fibrogenesis Through Sympathetic Hyperactivity After Focal Cerebral Infarction. Transl Stroke Res 2021. [PMID: 33713029 DOI: 10.1007/s12975-021-00900-w] [Reference Citation Analysis]
82 Kruik-Kollöffel WJ, van der Palen J, Doggen CJM, van Maaren MC, Kruik HJ, Heintjes EM, Movig KLL, Linssen GCM. Heart failure medication after a first hospital admission and risk of heart failure readmission, focus on beta-blockers and renin-angiotensin-aldosterone system medication: A retrospective cohort study in linked databases. PLoS One 2020;15:e0244231. [PMID: 33351823 DOI: 10.1371/journal.pone.0244231] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. Br J Sports Med 2015;49:1414-22. [PMID: 26476429 DOI: 10.1136/bjsports-2015-f5577rep] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
84 Gupta P, Voors AA, Patel P, Lane D, Anker SD, Cleland JGF, Dickstein K, Filippatos G, Lang CC, van Veldhuisen DJ, Metra M, Zannad F, Samani NJ, Jones DJL, Squire IB, Ng LL. Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study). Eur J Heart Fail 2021;23:1182-90. [PMID: 33759308 DOI: 10.1002/ejhf.2160] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Jurgens CY, Goodlin S, Dolansky M, Ahmed A, Fonarow GC, Boxer R, Arena R, Blank L, Buck HG, Cranmer K, Fleg JL, Lampert RJ, Lennie TA, Lindenfeld J, Piña IL, Semla TP, Trebbien P, Rich MW; American Heart Association Council on Quality of Care and Outcomes Research., Heart Failure Society of America. Heart failure management in skilled nursing facilities: a scientific statement from the American Heart Association and the Heart Failure Society of America. J Card Fail 2015;21:263-99. [PMID: 25863664 DOI: 10.1016/j.cardfail.2015.02.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
86 Vaduganathan M, Gheorghiade M, Butler J. Expanding the Scope of the “Polypill” to Heart Failure. Journal of Cardiac Failure 2013;19:540-1. [DOI: 10.1016/j.cardfail.2013.05.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
87 Choi KH, Lee GY, Choi JO, Jeon ES, Lee HY, Lee SE, Kim JJ, Chae SC, Baek SH, Kang SM, Choi DJ, Yoo BS, Kim KH, Cho MC, Park HY, Oh BH. The mortality benefit of carvedilol vs bisoprolol in patients with heart failure with reduced ejection fraction. Korean J Intern Med. 2019;34:1030-1039. [PMID: 30317846 DOI: 10.3904/kjim.2018.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
88 Liu Y, Zhou X, Qin B, Del Giovane C, Zhang Y, Xie P. Efficacy, quality of life, and acceptability outcomes of atypical antipsychotic augmentation treatment for treatment-resistant depression: protocol for a systematic review and network meta-analysis. Syst Rev 2014;3:133. [PMID: 25373601 DOI: 10.1186/2046-4053-3-133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
89 Ouwerkerk W, Voors A, Anker S, Cleland J, Dickstein K, Filippatos G, van der Harst P, Hillege H, Lang C, ter Maaten J, Ng L, Ponikowski P, Samani N, van Veldhuisen D, Zannad F, Metra M, Zwinderman A. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. European Heart Journal 2017;38:1883-90. [DOI: 10.1093/eurheartj/ehx026] [Cited by in Crossref: 175] [Cited by in F6Publishing: 141] [Article Influence: 43.8] [Reference Citation Analysis]
90 Valentim Gonçalves A, Pereira-da-Silva T, Galrinho A, Rio P, Moura Branco L, Soares R, Feliciano J, Ilhão Moreira R, Cruz Ferreira R. Antiarrhythmic Effect of Sacubitril-Valsartan: Cause or Consequence of Clinical Improvement? J Clin Med 2019;8:E869. [PMID: 31216679 DOI: 10.3390/jcm8060869] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
91 Ali DC, Naveed M, Gordon A, Majeed F, Saeed M, Ogbuke MI, Atif M, Zubair HM, Changxing L. β-Adrenergic receptor, an essential target in cardiovascular diseases. Heart Fail Rev 2020;25:343-54. [PMID: 31407140 DOI: 10.1007/s10741-019-09825-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 18.0] [Reference Citation Analysis]
92 Tan EC, Bell JS, Lu CY, Toh S, Wucherer D. National Trends in Outpatient Antihypertensive Prescribing in People with Dementia in the United States. JAD 2016;54:1425-35. [DOI: 10.3233/jad-160470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
93 Chimenti I, Pagano F, Sciarretta S, Marullo AG, Greco E, Tonelli E, Peruzzi M, Cavarretta E, Biondi-Zoccai G, Frati G. Cardiac Recovery During Long-Term LVAD: Is There an Interaction Between Beta-Blockers and Cardiac Progenitor Cells? J Am Coll Cardiol 2017;69:1880-1. [PMID: 28385324 DOI: 10.1016/j.jacc.2016.11.092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Safi S, Sethi NJ, Nielsen EE, Feinberg J, Jakobsen JC, Gluud C. Beta-blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database Syst Rev 2019;12:CD012484. [PMID: 31845756 DOI: 10.1002/14651858.CD012484.pub2] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
95 Iyngkaran P, Toukhsati SR, Thomas MC, Jelinek MV, Hare DL, Horowitz JD. A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure. Clin Med Insights Cardiol 2016;10:163-71. [PMID: 27773994 DOI: 10.4137/CMC.S38444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
96 Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, Boothroyd DB, Hlatky MA. Beta-Blocker Therapy and Cardiac Events Among Patients With Newly Diagnosed Coronary Heart Disease. Journal of the American College of Cardiology 2014;64:247-52. [DOI: 10.1016/j.jacc.2014.04.042] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 10.1] [Reference Citation Analysis]
97 Cvan Trobec K, Grabnar I, Kerec Kos M, Vovk T, Trontelj J, Anker SD, Rosano G, Lainscak M. Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. Eur J Clin Pharmacol 2016;72:813-22. [PMID: 26996442 DOI: 10.1007/s00228-016-2041-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
98 Nayyar S, Roberts-Thomson KC, Hasan MA, Sullivan T, Harrington J, Sanders P, Baumert M. Autonomic modulation of repolarization instability in patients with heart failure prone to ventricular tachycardia. Am J Physiol Heart Circ Physiol 2013;305:H1181-8. [PMID: 23934852 DOI: 10.1152/ajpheart.00448.2013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
99 Frommeyer G, Eckardt L. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol 2016;13:36-47. [PMID: 26194552 DOI: 10.1038/nrcardio.2015.110] [Cited by in Crossref: 80] [Cited by in F6Publishing: 67] [Article Influence: 13.3] [Reference Citation Analysis]
100 Dhar I, Svingen GFT, Olsen T, Lysne V, Bjørnestad EØ, Ueland PM, Nygård OK. β-blocker use and risk of all-cause mortality in patients with coronary heart disease: effect modification by serum vitamin A. Eur J Prev Cardiol 2021:zwaa158. [PMID: 33709106 DOI: 10.1093/eurjpc/zwaa158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Safi S, Sethi NJ, Korang SK, Nielsen EE, Feinberg J, Gluud C, Jakobsen JC. Beta-blockers in patients without heart failure after myocardial infarction. Cochrane Database Syst Rev 2021;11:CD012565. [PMID: 34739733 DOI: 10.1002/14651858.CD012565.pub2] [Reference Citation Analysis]
102 Liappas G, González-Mateo G, Aguirre AR, Abensur H, Albar-Vizcaino P, Parra EG, Sandoval P, Ramírez LG, Del Peso G, Acedo JM, Bajo MA, Selgas R, Sánchez Tomero JA, López-Cabrera M, Aguilera A. Nebivolol, a β1-adrenergic blocker, protects from peritoneal membrane damage induced during peritoneal dialysis. Oncotarget 2016;7:30133-46. [PMID: 27102153 DOI: 10.18632/oncotarget.8780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
103 Bonten TN, Plaizier CE, Snoep JJ, Stijnen T, Dekkers OM, van der Bom JG. Effect of β-blockers on platelet aggregation: a systematic review and meta-analysis. Br J Clin Pharmacol 2014;78:940-9. [PMID: 24730697 DOI: 10.1111/bcp.12404] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
104 Thaper A, Kulik A. Rationale for administering beta-blocker therapy to patients undergoing coronary artery bypass surgery: a systematic review. Expert Opin Drug Saf 2018;17:805-13. [PMID: 30037300 DOI: 10.1080/14740338.2018.1504019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
105 Pagano F, Angelini F, Siciliano C, Tasciotti J, Mangino G, De Falco E, Carnevale R, Sciarretta S, Frati G, Chimenti I. Beta2-adrenergic signaling affects the phenotype of human cardiac progenitor cells through EMT modulation. Pharmacol Res 2018;127:41-8. [PMID: 28099883 DOI: 10.1016/j.phrs.2017.01.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
106 Njegic A, Wilson C, Cartwright EJ. Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias. Front Physiol 2020;11:1068. [PMID: 33013458 DOI: 10.3389/fphys.2020.01068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
107 Alabed S, Sabouni A, Al Dakhoul S, Bdaiwi Y, Frobel-Mercier AK. Beta-blockers for congestive heart failure in children. Cochrane Database Syst Rev 2016;:CD007037. [PMID: 26820557 DOI: 10.1002/14651858.CD007037.pub3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
108 Savarese G, Orsini N, Hage C, Vedin O, Cosentino F, Rosano GMC, Dahlström U, Lund LH. Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. JACC Heart Fail 2018;6:246-56. [PMID: 29428439 DOI: 10.1016/j.jchf.2017.12.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
109 Moroni F, Gertz Z, Azzalini L. Relief of Ischemia in Ischemic Cardiomyopathy. Curr Cardiol Rep 2021;23:80. [PMID: 34081220 DOI: 10.1007/s11886-021-01520-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Jurgens CY, Goodlin S, Dolansky M, Ahmed A, Fonarow GC, Boxer R, Arena R, Blank L, Buck HG, Cranmer K, Fleg JL, Lampert RJ, Lennie TA, Lindenfeld J, Piña IL, Semla TP, Trebbien P, Rich MW; American Heart Association Council on Quality of Care and Outcomes Research and the Heart Failure Society of America. Heart failure management in skilled nursing facilities: a scientific statement from the American Heart Association and the Heart Failure Society of America. Circ Heart Fail 2015;8:655-87. [PMID: 25855686 DOI: 10.1161/HHF.0000000000000005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
111 Cvetinovic N, Sekularac N, Haehling SV, Tahirovic E, Inkrot S, Lainscak M, Apostolovic S, Putnikovic B, Waagstein F, Gelbrich G, Aleksic A, Loncar G, Düngen HD. The β-blocker uptitration in elderly with heart failure regarding biomarker levels: CIBIS-ELD substudy. Biomark Med 2018;12:1261-70. [PMID: 30450925 DOI: 10.2217/bmm-2018-0136] [Reference Citation Analysis]
112 Thomopoulos C, Bazoukis G, Tsioufis C, Mancia G. Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials. J Hypertens 2020;38:1669-81. [PMID: 32649628 DOI: 10.1097/HJH.0000000000002523] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
113 Biondi-Zoccai G, Abbate A, Benedetto U, Palmerini T, D'Ascenzo F, Frati G. Network meta-analysis for evidence synthesis: what is it and why is it posed to dominate cardiovascular decision making? Int J Cardiol 2015;182:309-14. [PMID: 25585376 DOI: 10.1016/j.ijcard.2015.01.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
114 Lee PH, Park GM, Han S, Kim YG, Lee JY, Roh JH, Lee JH, Kim YH, Lee SW. Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management. Sci Rep 2020;10:22121. [PMID: 33335231 DOI: 10.1038/s41598-020-79214-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Poels EM, da Costa Martins PA, van Empel VPM. Adaptive capacity of the right ventricle: why does it fail? American Journal of Physiology-Heart and Circulatory Physiology 2015;308:H803-13. [DOI: 10.1152/ajpheart.00573.2014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
116 Abarquez RF Jr, Reganit PF, Chungunco CN, Alcover J, Punzalan FE, Reyes EB, Cunanan EL. Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy? ASEAN Heart J 2016;24:4. [PMID: 27054142 DOI: 10.7603/s40602-016-0004-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
117 Moretti C, Grosso Marra W, D'Ascenzo F, Omedè P, Cannillo M, Libertucci D, Fusaro E, Meynet I, Giordana F, Salera D, Annone U, Chen SL, Marra S, Gaita F. Beta blocker for patients with pulmonary arterial hypertension: A single center experience. Int J Cardiol 2015;184:528-32. [PMID: 25767009 DOI: 10.1016/j.ijcard.2015.02.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
118 Wu PH, Lin YT, Liu JS, Tsai YC, Kuo MC, Chiu YW, Hwang SJ, Carrero JJ. Comparative effectiveness of bisoprolol and carvedilol among patients receiving maintenance hemodialysis. Clin Kidney J 2021;14:983-90. [PMID: 33779636 DOI: 10.1093/ckj/sfaa248] [Reference Citation Analysis]
119 Loop MS, van Dyke MK, Chen L, Safford MM, Kilgore ML, Brown TM, Durant RW, Levitan EB. Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction. J Card Fail 2019;25:343-51. [PMID: 30339796 DOI: 10.1016/j.cardfail.2018.10.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
120 Chatterjee S, Udell JA, Sardar P, Lichstein E, Ryan JJ. Comparable Benefit of β-Blocker Therapy in Heart Failure Across Regions of the World: Meta-analysis of Randomized Clinical Trials. Canadian Journal of Cardiology 2014;30:898-903. [DOI: 10.1016/j.cjca.2014.03.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
121 Matarrese P, Maccari S, Vona R, Gambardella L, Stati T, Marano G. Role of β-Adrenergic Receptors and Estrogen in Cardiac Repair after Myocardial Infarction: An Overview. Int J Mol Sci 2021;22:8957. [PMID: 34445662 DOI: 10.3390/ijms22168957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev 2015;20:193-201. [DOI: 10.1007/s10741-014-9453-8] [Cited by in Crossref: 64] [Cited by in F6Publishing: 57] [Article Influence: 9.1] [Reference Citation Analysis]
123 Packer M, Metra M. Guideline-directed medical therapy for heart failure does not exist: a non-judgmental framework for describing the level of adherence to evidence-based drug treatments for patients with a reduced ejection fraction. Eur J Heart Fail 2020;22:1759-67. [PMID: 32432391 DOI: 10.1002/ejhf.1857] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
124 Bennett A, Parto P, Krim SR. Hypertension and ethnicity. Current Opinion in Cardiology 2016;31:381-6. [DOI: 10.1097/hco.0000000000000293] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
125 Zhang X, Shen C, Zhai S, Liu Y, Yue WW, Han L. A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure. Exp Ther Med 2016;12:2489-96. [PMID: 27703506 DOI: 10.3892/etm.2016.3657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
126 Farha S, Saygin D, Park MM, Cheong HI, Asosingh K, Comhair SA, Stephens OR, Roach EC, Sharp J, Highland KB, DiFilippo FP, Neumann DR, Tang WHW, Erzurum SC. Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial. JCI Insight 2017;2:95240. [PMID: 28814664 DOI: 10.1172/jci.insight.95240] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 11.5] [Reference Citation Analysis]
127 O'Neal WT, Sandesara PB, Samman-Tahhan A, Kelli HM, Hammadah M, Soliman EZ. Heart rate and the risk of adverse outcomes in patients with heart failure with preserved ejection fraction. Eur J Prev Cardiol 2017;24:1212-9. [PMID: 28482692 DOI: 10.1177/2047487317708676] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
128 Paolillo S, Mapelli M, Bonomi A, Corrà U, Piepoli M, Veglia F, Salvioni E, Gentile P, Lagioia R, Metra M, Limongelli G, Sinagra G, Cattadori G, Scardovi AB, Carubelli V, Scrutino D, Badagliacca R, Raimondo R, Emdin M, Magrì D, Correale M, Parati G, Caravita S, Spadafora E, Re F, Cicoira M, Frigerio M, Bussotti M, Minà C, Oliva F, Battaia E, Belardinelli R, Mezzani A, Pastormerlo L, Di Lenarda A, Passino C, Sciomer S, Iorio A, Zambon E, Guazzi M, Pacileo G, Ricci R, Contini M, Apostolo A, Palermo P, Clemenza F, Marchese G, Binno S, Lombardi C, Passantino A, Perrone Filardi P, Agostoni P. Prognostic role of β-blocker selectivity and dosage regimens in heart failure patients. Insights from the MECKI score database. Eur J Heart Fail 2017;19:904-14. [PMID: 28233458 DOI: 10.1002/ejhf.775] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
129 Iyngkaran P, Liew D, McDonald P, Thomas MC, Reid C, Chew D, Hare DL. Phase 4 Studies in Heart Failure - What is Done and What is Needed? Curr Cardiol Rev. 2016;12:216-230. [PMID: 27280303 DOI: 10.2174/1573403x12666160606121458] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
130 Sousa-uva* M, Head SJ, Milojevic M, Collet J, Landoni G, Castella M, Dunning J, Gudbjartsson T, Linker NJ, Sandoval E, Thielmann M, Jeppsson A, Landmesser* U. 2017 EACTS Guidelines on perioperative medication in adult cardiac surgery. European Journal of Cardio-Thoracic Surgery 2018;53:5-33. [DOI: 10.1093/ejcts/ezx314] [Cited by in Crossref: 141] [Cited by in F6Publishing: 110] [Article Influence: 35.3] [Reference Citation Analysis]
131 Staszewsky L, Cortesi L, Tettamanti M, Dal Bo GA, Fortino I, Bortolotti A, Merlino L, Latini R, Roncaglioni MC, Baviera M. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. Eur J Heart Fail 2016;18:840-8. [PMID: 27098360 DOI: 10.1002/ejhf.519] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
132 Younis NK, Ghoubaira JA, Bassil EP, Tantawi HN, Eid AH. Metal-based nanoparticles: Promising tools for the management of cardiovascular diseases. Nanomedicine 2021;36:102433. [PMID: 34171467 DOI: 10.1016/j.nano.2021.102433] [Reference Citation Analysis]
133 Girouard C, Grégoire JP, Poirier P, Moisan J. Factors associated with β-blocker initiation and discontinuation in a population-based cohort of seniors newly diagnosed with heart failure. Patient Prefer Adherence 2016;10:1811-21. [PMID: 27695300 DOI: 10.2147/PPA.S109054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
134 Biondi Zoccai G, Frati G, Romagnoli E, Sciarretta S, Abbate A. Final results of the ISCHEMIA trial: distinguishing mass media coverage from clinical interpretation. Minerva Cardioangiol 2020;68:9-14. [PMID: 31820619 DOI: 10.23736/S0026-4725.19.05106-5] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Chakraborty A, Chatterjee S. Convergence in findings from randomized trials and elaborately analysed observational data on mortality reduction with carvedilol in heart failure in comparison with metoprolol. Eur J Heart Fail 2014;16:595-7. [PMID: 24863629 DOI: 10.1002/ejhf.108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
136 Pasternak B, Mattsson A, Svanström H, Hviid A. Comparative effectiveness of bisoprolol and metoprolol succinate in patients with heart failure. Int J Cardiol 2015;190:4-6. [PMID: 25912106 DOI: 10.1016/j.ijcard.2015.03.441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
137 Hanigan S, Didomenico RJ. Emerging Therapies for Acute and Chronic Heart Failure: Hope or Hype? Journal of Pharmacy Practice 2016;29:46-57. [DOI: 10.1177/1933719115615877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
138 Gencer B, Rodondi N, Auer R, Räber L, Klingenberg R, Nanchen D, Carballo D, Vogt P, Carballo S, Meyer P, Matter CM, Windecker S, Lüscher TF, Mach F. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. Eur J Intern Med 2015;26:56-62. [PMID: 25582072 DOI: 10.1016/j.ejim.2014.12.014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
139 Volpe M, de la Sierra A, Kreutz R, Laurent S, Manolis AJ. ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. High Blood Press Cardiovasc Prev 2014;21:137-47. [PMID: 24532183 DOI: 10.1007/s40292-014-0043-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
140 Kelly D, Hawdon G, Reeves J, Morris A, Cunningham M, Barrett J. Safety of intravenous metoprolol use in unmonitored wards: a single-centre observational study. Intern Med J 2015;45:934-8. [PMID: 26109478 DOI: 10.1111/imj.12842] [Reference Citation Analysis]
141 Chia N, Fulcher J, Keech A. Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart failure. Intern Med J 2016;46:653-62. [PMID: 26109136 DOI: 10.1111/imj.12839] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
142 D'Ascenzo F, Celentani D, Brustio A, Grosso A, Raposeiras-Roubín S, Abu-Assi E, Henriques JPS, Saucedo J, González-Juanatey JR, Wilton SB, Kikkert WJ, Nuñez-Gil I, Ariza-Sole A, Song X, Alexopoulos D, Liebetrau C, Kawaji T, Huczek Z, Nie SP, Fujii T, Correia L, Kawashiri MA, García-Acuña JM, Southern D, Alfonso E, Terol B, Garay A, Zhang D, Chen Y, Xanthopoulou I, Osman N, Möllmann H, Shiomi H, Kowara M, Filipiak K, Wang X, Yan Y, Fan JY, Ikari Y, Nakahayshi T, Sakata K, Yamagishi M, Kalpak O, Kedev S, Moretti C, D'Amico M, Gaita F. Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry. Am J Cardiovasc Drugs 2018;18:299-309. [PMID: 29691803 DOI: 10.1007/s40256-018-0273-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
143 Fröhlich H, Torres L, Täger T, Schellberg D, Corletto A, Kazmi S, Goode K, Grundtvig M, Hole T, Katus HA, Cleland JGF, Atar D, Clark AL, Agewall S, Frankenstein L. Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. Clin Res Cardiol 2017;106:711-21. [PMID: 28434020 DOI: 10.1007/s00392-017-1115-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
144 Chatterjee S, Kim J, Dahhan A, Choudhary G, Sharma S, Wu WC. Use of high-sensitivity troponin assays predicts mortality in patients with normal conventional troponin assays on admission-insights from a meta-analysis. Clin Cardiol 2013;36:649-53. [PMID: 24037966 DOI: 10.1002/clc.22196] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]